Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment
PLOS One · 2025
DOI: 10.1371/journal.pone.0325561 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Elizabeth S Munroe und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Monoclonal, Antibodies, Viral. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NHLBI NIH HHS, Foundation for the National Institutes of Health, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Neutralizing monoclonal antibodies (nMAbs) have been used to treat COVID-19 and are increasingly being used to treat other infections. However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.
Methods
We compared 28 and 90-day anti-SARS-CoV-2 spike protein neutralization activity and anti-SARS-CoV-2 nucleocapsid response for patients hospitalized with COVID-19 infection randomized to receive nMAbs or placebo in the large platform ACTIV-3/TICO trials. We pooled results from four trials of anti-spike nMAbs. For most tested agents, measurements of the spike protein response reflect both the therapeutic and endogenous immune response. Anti-nucleocapsid levels reflect only the endogenous immune response. Data are summarized as mean differences in percent binding inhibition (anti-spike) and signal-to-cutoff (S/C) ratio (anti-nucleocapsid). Linear mixed effects models were fit to compare the longitudinal trajectory between treatment and placebo groups.
Results
Of 2,254 participants in the ACTIV-3/TICO trials modified intention-to-treat population, 2,149 (95.3%) had antibody measures at baseline and at least 1 follow-up day (day 1, 3, or 5) and were included in this analysis. Antibody measures were available for 1,556 (72.4%) participants at day 28 and 1,429 (66.5%) participants at day 90. In participants who received nMAbs, anti-spike neutralization activity was higher at day 28 (mean difference in percent binding inhibition: 7.1% [95%CI: 5.3, 8.9], p < 0.001) and day 90 (mean difference in percent binding inhibition: 7.2% [95% CI: 5.4, 9.0], p < 0.001). Anti-nucleocapsid response was similar at day 28 (mean difference in S/C ratio: 0.02 [95%CI: −0.11, 0.15], p = 0.75) and day 90 (mean difference in S/C ratio: 0.08 [95% CI: −0.05, 0.21], p = 0.22). Similar patterns were observed in all trials.
Conclusions
In patients hospitalized with COVID-19, treatment with nMAbs did not decrease long-term anti-nucleocapsid response compared to placebo, suggesting neutralizing therapies do not suppress the endogenous humoral immune response in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
- Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States of America.
- VA Center for Clinical Management Research, Ann Arbor, Michigan, United States of America.
- VA Portland Health Care System, and the Department of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America.
- Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
- MRC Clinical Trials Unit, University College London, London, United Kingdom.
ORCID-Profile: Elizabeth S Munroe, Anna L Goodman, Timothy J Hatlen, Thomas L Holland
Förderung
- NHLBI NIH HHS
- Foundation for the National Institutes of Health
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- National Research Foundation Singapore
- Medical Research Council
Zitieren
APA
Munroe, E. S., Grandits, G. A., Hyzy, R. C., Prescott, H. C., Barrett, T. W., Dewar, R. L., Engen, N., Goodman, A. L., Hatlen, T. J., Highbarger, H., Holland, T. L., Hughes, G., Jensen, T. O., Khan, M. A., Kalomenidis, I., Kang, N., Laverdure, S., Manian, P., Menon, V., …, & STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups (2025). Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLOS One. https://doi.org/10.1371/journal.pone.0325561
Vancouver
Munroe ES, Grandits GA, Hyzy RC, Prescott HC, Barrett TW, Dewar RL, et al. Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLOS One. 2025. doi:10.1371/journal.pone.0325561
BibTeX
@article{Munroe2025,
author = {Munroe, Elizabeth S and Grandits, Greg A and Hyzy, Robert C and Prescott, Hallie C and Barrett, Thomas W and Dewar, Robin L and Engen, Nicole and Goodman, Anna L and Hatlen, Timothy J and Highbarger, Helene and Holland, Thomas L and Hughes, Gareth and Jensen, Tomas O and Khan, Muhammad A and Kalomenidis, Ioannis and Kang, Nayon and Laverdure, Sylvain and Manian, Prasad and Menon, Vidya and Patel, Ravi and Ramachandruni, Srikanth and Rehman, Tauseef and Shaw-Saliba, Kathryn and Røge, Birgit Thorup and Vock, David M and Weintrob, Amy C and Young, Barnaby E and Frosch, Anne P and STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups, STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups},
title = {Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325561}
}
EUVIMED